{"title":"与蔡丽慧的对话。","authors":"","doi":"10.1101/sqb.2018.83.038042","DOIUrl":null,"url":null,"abstract":"Gary Stix: Could you talk a little bit about the whole Alzheimer’s field, which is a focus of a lot of your work, and the current state of the Alzheimer’s field? There are enormous numbers of drugs, but I always hear about 99-point-something that just have failed. There’s a real worry in the field that there’s no clear directions forward. Your work approaches some of the problems of the biology of Alzheimer’s in new ways. Could talk about what you think that problem is?","PeriodicalId":72635,"journal":{"name":"Cold Spring Harbor symposia on quantitative biology","volume":"83 ","pages":"284-286"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Conversation with Li-Huei Tsai.\",\"authors\":\"\",\"doi\":\"10.1101/sqb.2018.83.038042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Gary Stix: Could you talk a little bit about the whole Alzheimer’s field, which is a focus of a lot of your work, and the current state of the Alzheimer’s field? There are enormous numbers of drugs, but I always hear about 99-point-something that just have failed. There’s a real worry in the field that there’s no clear directions forward. Your work approaches some of the problems of the biology of Alzheimer’s in new ways. Could talk about what you think that problem is?\",\"PeriodicalId\":72635,\"journal\":{\"name\":\"Cold Spring Harbor symposia on quantitative biology\",\"volume\":\"83 \",\"pages\":\"284-286\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cold Spring Harbor symposia on quantitative biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/sqb.2018.83.038042\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/4/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cold Spring Harbor symposia on quantitative biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/sqb.2018.83.038042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/4/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Gary Stix: Could you talk a little bit about the whole Alzheimer’s field, which is a focus of a lot of your work, and the current state of the Alzheimer’s field? There are enormous numbers of drugs, but I always hear about 99-point-something that just have failed. There’s a real worry in the field that there’s no clear directions forward. Your work approaches some of the problems of the biology of Alzheimer’s in new ways. Could talk about what you think that problem is?